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ds Persistent Ketamine Use a Valid Model of the
ognitive and Oculomotor Deficits in Schizophrenia?
elia J.A. Morgan, Vyv Huddy, Michelle Lipton, H. Valerie Curran, and Eileen M. Joyce
ackground: Acute ketamine has been shown to model features of schizophrenia such as psychotic symptoms, cognitive deficits and
mooth pursuit eye movement dysfunction. There have been suggestions that chronic ketamine may also produce an analogue of the
isorder. In this study, we investigated the effect of persistent recreational ketamine use on tests of episodic and working memory and on
culomotor tasks of smooth pursuit and pro- and antisaccades.
ethods: Twenty ketamine users were compared with 1) 20 first-episode schizophrenia patients, 2) 17 polydrug control subjects who did
ot use ketamine but were matched to the ketamine users for other drug use, and 3) 20 non-drug-using control subjects. All groups were
atched for estimated premorbid IQ.
esults: Ketamine users made more antisaccade errors than both control groups but did not differ from patients. Ketamine users
erformed better than schizophrenia patients on smooth pursuit, antisaccade metrics, and both memory tasks but did not differ from
ontrol groups.
onclusions: Problems inhibiting reflexive eyemovementsmay be a consequence of repeated ketamine self-administration. The absence
f any other oculomotor or cognitive deficit present in schizophrenia suggests that chronic self-administration of ketamine may not be a
ood model of these aspects of the disorder.ey Words: Antisaccades, drug abuse, eye tracking, ketamine,
chizophrenia, smooth pursuit, spatial working memory, verbal
emory
cute administration of ketamine in healthy volunteers
elicits psychotic symptoms and cognitive deficits similar
to those seen in schizophrenia (1–3). Recreational ket-
mine use is associated with psychotic symptoms such as
elusions and episodic memory impairment, also seen in schizo-
hrenia (4). Chronic ketamine administration has been proposed
s a more representative model of cognitive impairments seen in
chizophrenia (5). People who persistently self-administer ket-
mine provide a naturalistic opportunity to investigate whether
here are similarities in the behaviors disrupted in schizophrenia
nd following chronic N-methyl-D-aspartate (NMDA) receptor
ntagonism.
In addition to cognitive impairment, schizophrenia is associ-
ted with oculomotor deficits, particularly in smooth pursuit (6)
nd the ability to inhibit reflexive eye movements when perform-
ng the antisaccade task (7). Three previous studies have found
bnormal smooth pursuit following an acute dose of ketamine
8–10), but there have been no reports of oculomotor function
ollowing persistent ketamine use.
In the current study, we wished to examine whether
ersistent ketamine use is associated with oculomotor and
ognitive deficits typical of schizophrenia. We compared
ecreational ketamine users with IQ- and age-matched early-
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oi:10.1016/j.biopsych.2008.10.045phase schizophrenia patients. We also tested a healthy control
group and a group to control for the effect of nonketamine
substance use. We hypothesized that similar abnormalities
would be observed in persistent ketamine users and schizo-
phrenia patients.
Methods andMaterials
Participants
Twenty ketamine users were recruited from a database and
via a snowball sampling technique (11). Because the ketamine
users also used other drugs, 17 polydrug users who did not use
ketamine but who were matched with the ketamine group for
other recreational drug use were also recruited. Inclusion criteria
for the ketamine group were 1) age between 18 and 50, 2)
ketamine use for at least 1 year and at least twice per month, 3)
ketamine use within the last month but not in the last 3 days
(verified by urinanalysis), and 4) absence of current or past
history of mental health problems.
Twenty patients with schizophrenia and 20 healthy control
subjects were selected for comparison on the basis of age and
National Adult Reading Test IQ (12) from a prospective, longi-
tudinal study of first-episode psychosis in West London. Inclu-
sion criteria and clinical assessments have previously been
described in detail (13). Briefly, patients had presented with a
psychotic illness for the first time and received no more than 12
weeks of antipsychotic medication. All 20 patients included in
this study met DSM-IV diagnostic criteria for schizophrenia.
Eighteen were taking antipsychotic medication (15 of whom
were taking second-generation medications). Twenty healthy
control subjects were recruited from the same catchment area as
the patients; exclusion criteria were a past or family history of
psychiatric illness, previous head injury, or other illness affecting
brain function and drug or alcohol abuse or dependence.
The local Research Ethics Committees approved the study. All
participants gave written informed consent and reimbursed for
their time.
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wculomotor Tasks
Apparatus. Eye movements were recorded with an SR-
esearch (Mississauga, Canada) Eyelink eye tracker. Three cam-
ras simultaneously recorded the position of both eyes and the
ead, allowing gaze position to be computed without head
estraint. Participants viewed a 21-inch monitor from a distance
f 60 cm, which subtended a visual angle of 40 horizontally and
0 vertically.
Smooth Pursuit. Stimuli consisted of a red circle presented
gainst a black background. The circle subtended approxi-
ately .5 of visual angle and, starting on the left, moved
orizontally backward and forward  27. Two blocks of six
ycles of constant velocity pursuit were generated. Each block
as preceded by a drift correct procedure that lasted approx-
mately 3 sec. In the first block, the target moved at a constant
elocity of 5 of visual angle per second; in the second block
his increased to 10 per second, and in the third block, this
urther increased to 20 per second.
Prosaccade and Antisaccade Tasks. Each trial comprised the
ollowing sequence: 1) a central fixation dot appeared at the
eginning of each trial; 2) after 800 msec, the central dot
isappeared, a peripheral target dot appeared simultaneously for
000 msec, and a 200-msec click signal sounded. For prosaccade
able 1. Group Characteristics
Ketamine Users Schizophrenia
(n 20) (n 20)
ge at Testing (range) 28.2 (20–42) 24.8 (17–48)
ART IQ (range) 114.25 (93–126) 111.05 (105–120)
ge Left Education (range) 18.85 (16–21) 17.7 (15–21)
ex (male/female) 15/5 14/6
mokers (n) 12 14
lcohol Users (n) 20 18
NART, National Adult Reading Test.
a2 statistic.
able 2. Group Performance for Smooth Pursuit and Prosaccade and Antis
Ketamine
Users (SD)
Schizophrenia
Patients (SD)
mooth Pursuit
° Velocity Gain 1.00 (.05) .96 (.07)a
0° Velocity Gain .99 (.06) .96 (.07)a
0° Velocity Gain .95 (.11) .87 (.11)a
rosaccades
atency (msec) 153.01 (21.50) 168.34 (56.50)
rimary Saccade Gain .94 (.06) .92 (.06)
inal Eye Position 1.0 (.01) .93 (.20)
ntisaccades
atency (msec) 264.31 (39.80) 377.29 (99.70)b
rimary Saccade Gain 1.29 (.41) .84 (.47)b
inal Eye Position 1.25 (.34) .97 (.25)a
Measures are mean (SD).
a .05 for comparisons schizophrenia versus ketamine, polydrug versus
b .01 for comparisons schizophrenia versus ketamine, polydrug versus
cKruskall Wallis 2 approximation for nonparametric data.
ww.sobp.org/journaltrials, subjects were asked to direct their gaze as quickly and
accurately as possible to the new dot and then return to the
central fixation point. For antisaccade trials, subjects were in-
structed to move their eyes rapidly toward an equidistant posi-
tion in space, but in the opposite direction to the peripheral
stimulus, that is, to the mirror-image location. There were 24
trials for each condition.
Neuropsychology
The Rey Auditory Verbal Learning (RAVLT) (14). In trials
1–5, subjects were read the same list of 15 nouns and asked to
recall immediately afterward as many as possible. A second
interference list was then read followed by a free recall test.
Delayed free recall for the original list was tested, without
reminding, after a short and long (30-min) delay, followed by a
test of recognition memory.
Spatial Working Memory (15). Patients were required to
“open” sets of boxes, varying between three and eight in
number, to find tokens. Errors were recorded when boxes in
which tokens had been found were reopened; a measure of
strategy was also taken.
lydrug-Using Control Non-Drug-Using Control
F(3,73) p(n 17) (n 20)
26.47 (18–30) 30.8 (21–51) 2.64 .06
110.2 (92–122) 112.3 (105–121) 1.04 .38
17.94 (16–21) 18.5 (16–21) 1.36 .20
17/0 11/9 9.91a .02
8 Not recorded 4.25a .119
20 Not recorded 2.03a .362
e Metrics
rug Control
jects (SD)
Non-Drug-Using Control
Subjects (SD)
Main Effects and
Interaction
01 (.05) 1.00 (.04) Target Speed
[F(2,149) 27.12, p
.001]
01 (.06) 1.00 (.04) Group
[F(3,70)4.06,p .010]
98 (.06) .97 (.06) Target SpeedGroup
[F(6,140) 1.67, p
.130]
F(3,73) p Value
27 (21.59) 166.00 (19.01) 1.10 .355
94 (.05) .96 (.06) 1.85 .150
0 (.00) 1.0 (.02) 2.71c .440
F(3,73) p Value
31 (29.09) 282.29 (48.57) 14.58 .001
28 (.58) 1.02 (.53) 3.67 .016
36 (.56) 1.27 (.52) 10.91c .012
mine, and control versus ketamine.
mine, and control versus ketamine.Poaccad
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Pursuit Task. Eye movements were analyzed using custom
oftware written in LabVIEW. The software extracted eye posi-
ion data consisting of a series of x axis pixel coordinates
ampled every 2 msec. Sections of pursuit that included intrusive
accades or corrective saccades, blinks, or fixations were not
ncluded in the analysis. Within each operator-defined period of
ursuit, the program calculated the velocity gain (ratio of eye
elocity to target velocity), which provides an accurate measure
f the ability of the smooth pursuit system to match eye velocity
o target velocity (16).
Prosaccade and Antisaccade Tasks. The detection of sac-
ades was based on a velocity criterion of 30°/sec in addition to
cceleration across three consecutive samples. In both para-
igms, spatial accuracy measures of primary saccade gain (sac-
adic amplitude divided by target amplitude) and final eye
osition (the longest stable period of fixation after any corrective
accades had been made, expressed as gain) as well as latency to
erform a correct antisaccades (milliseconds) were calculated. In
he antisaccade task, the number of errors when subjects made
n initial saccade toward the target was recorded.
tatistical Analysis
Data were analyzed with SPSS Version 11.5. Repeated-measures
nalysis of variance (ANOVA) was used to compare the groups for
he smooth pursuit data, with Group as a between-subjects factor.
ther data were analyzed with one-way ANOVAs; Kruskall-Wallis
ests were used when data were nonparametrically distributed.
hen significant differences emerged, Bonferroni-corrected
lanned comparisons were conducted: ketamine versus non-
rug, ketamine versus polydrug, and ketamine versus schizo-
hrenia.
10
15
20
25
30
35
40
45
50
55
Schizophrenia Ketamine + Polydrug Polydrug control Nondrug control
%
 E
rr
or
s
igure 1. Antisaccade errors (bars represent standard error). Significant
ifferences (p .05) were observed between the ketamine group and both
he polydrug and non-drug-using control groups.
able 3. Group Performance on the Rey Auditory Verbal Learning Test (RA
orking Memory Task (SWM)
Ketamine
Users
Schizophrenia
Patients
VLT Free Recall 48.95 (6.10) 43.25 (9.67)a
VLT Interference 10.18 (1.79) 8.35 (2.28)b
VLT 30-min Free Recall 10.36 (2.32) 7.80 (2.65)
WM Strategy Score 31.09 (5.63) 32.50 (8.13)
WM Total Errors 15.68 (14.29) 30.40 (19.81)b
Measures are mean (standard deviation). Differences from ketamine g
etamine, control versus ketamine.
aNonsignificant trend.
bp .05.Results
Participants
See Table 1. There were no significant differences in esti-
mated premorbid IQ or age at which subjects left full-time
education. There was a significant difference in sex, reflecting
the absence of any female subjects in the polydrug using group.
There was a nonsignificant trend for an age difference between
the groups. When we examined the impact of age or sex on our
findings, neither significantly affected the outcome of the analy-
ses.
Drug Use
Ketamine was used for 2.7 ( 1.07) days/month over 3.23 (
1.26) years with 1.92 ( .86) g/session. There were no differ-
ences between ketamine and polydrug control groups in the
number of subjects taking other drugs regularly (cocaine: 8/20
vs. 5/17; cannabis: 11/20 vs. 8/17; ecstasy: 9/20 vs. 10/17).
Smoking and alcohol use data were not recorded for the nondrug
control subjects, but there were no significant differences be-
tween the other three groups in numbers of smokers or regular
drinkers.
Smooth Pursuit
See Table 2. Repeated-measures ANOVA of velocity gain
revealed a main effect of Target Speed and Group. Performance
worsened with increasing speed for all groups; schizophrenia
patients were worse than ketamine users (p  .020).
Prosaccades
See Table 2. There were no significant differences between
the groups.
Antisaccades
Groups differed in the number of antisaccade errors [Figure 1;
F (3,73)  4.34, p  .006] and oculomotor metrics (Table 2).
Ketamine users demonstrated more errors than nondrug (p 
.025) and polydrug (p  .048) control subjects but not
schizophrenia patients. For correct trials, schizophrenia pa-
tients were worse than ketamine users for antisaccade latency
(p  .001), final eye position (p  .041), and primary saccade
gain (p  .003).
Neuropsychology
See Table 3. There were group differences for all measures
except spatial working memory strategy. Ketamine users were
better than schizophrenia patients on verbal learning and
showed fewer spatial working memory errors (p  .05).
nd Cambridge Automated Neuropsychological Testing Battery Spatial
Polydrug Control
Subjects
Non-Drug-Using
Control Subject Fp
45.80 (6.80) 54.84 (5.48) 9.164 .001
9.67 (2.61) 11.47 (2.12) 6.854 .001
9.00 (2.14) 11.84 (2.61) 9.749 .001
32.53 (6.42) 32.58 (4.49) .275 .844
18.87 (15.59) 16.95 (13.06) 3.623 .017
in planned comparisons: schizophrenia versus ketamine, polydrug versusLVT) a
roupwww.sobp.org/journal
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wiscussion
Compared with matched groups of nonketamine polydrug
sers and non-drug-using control subjects, ketamine users made
ignificantly more antisaccade errors but were no different on
patial accuracy and latency of antisaccades or on accuracy of
mooth pursuit. Compared with schizophrenia patients, ket-
mine users were no different with respect to antisaccade errors
ut performed better on all other indices of oculomotor control;
hey also performed better on tests of verbal learning and spatial
orking memory. Although the patients were taking antipsy-
hotic medication, we have previously shown that smooth
ursuit and antisaccade performance is not impaired by treat-
ent in early-phase schizophrenia (17,18), and other studies
ave found that similar cognitive impairment is present in
ntreated groups (19), suggesting that this is not an explanation
f the worse performance of the patient group. Rather, our
esults indicate that persistent ketamine use may not be a good
odel of these aspects of schizophrenia, at least at the levels and
requency of intake described in this sample.
A possible explanation of the isolated increased antisaccade
rror rate, compared with other preserved antisaccade and
culomotor metrics, is that antisaccade errors relate to response
uppression and indicate a nonspecific impairment of inhibitory
ontrol common to many types of addiction (20). However,
ntisaccade errors were at normal levels in a group of nonket-
mine drug users who were otherwise matched for the range and
xtent of other substances used, although reports of other drug
se were reliant on self-report. Alternative explanations that
annot be distinguished in his study include the effect of
ersistent ketamine use on dopaminergic function or a preexist-
ng trait that predisposed this group to take the drug.
This study was supported by the UK Economic and Social
esearch Council (Grant No. RES-000-23-0945) and by the
ellcome Trust UK (Grant No. 064607).
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